1. Home
  2. RETO vs APRE Comparison

RETO vs APRE Comparison

Compare RETO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RETO

ReTo Eco-Solutions Inc.

HOLD

Current Price

$0.69

Market Cap

9.6M

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.90

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RETO
APRE
Founded
1999
2006
Country
China
United States
Employees
N/A
8
Industry
Multi-Sector Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
10.6M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
RETO
APRE
Price
$0.69
$0.90
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
2.0M
448.0K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.55
52 Week High
$4.66
$2.22

Technical Indicators

Market Signals
Indicator
RETO
APRE
Relative Strength Index (RSI) 43.47 55.63
Support Level $0.61 $0.90
Resistance Level $1.30 $0.98
Average True Range (ATR) 0.29 0.10
MACD -0.01 0.01
Stochastic Oscillator 20.18 55.57

Price Performance

Historical Comparison
RETO
APRE

About RETO ReTo Eco-Solutions Inc.

ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: